Sree Rayalaseema Hi-Strength Hypo growth ratios

·ChemicalsChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+4.6%−26.3%−47.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−3.9%−16.8%−37.8%
−4.1%−15.2%−36.9%
+3.1%+10.8%−48.8%
+4.5%+10.8%−48.8%
+4.2%+17.8%−1.5%
+5.4%+16.7%+6.6%
−39.9%−53.0%−2.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SRHHYPOLTD₹499.15

Sree Rayalaseema Hi-Strength Hypo Limited

· Chemicals
₹ CrorePeersGEMAROMADMCCSUDARCOLORJAYAGROGNKRONOXAMNPLSTCHEMFABPRIMOMcap ₹857 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-47.5-26.3+4.6—
EBITDA Growth—-37.8-16.8-3.9—
EBIT Growth—-36.9-15.2-4.1—
Net Income Growth—-48.8+10.8+3.1—
EPS Growth—-48.8+10.8+4.5—
Total Assets Growth—-1.5+17.8+4.2—
Total Equity Growth—+6.6+16.7+5.4—
Cash from Operations Growth—-2.0-53.0-39.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.